Get the Stockscreener App
77.11
1.15%
0.7098
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $77.11, with a volume of 9.57M.
It is up +1.15% in the last 24 hours and down -9.29% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$76.40
Open:
$76.94
24h Volume:
9.57M
Relative Volume:
0.62
Market Cap:
$193.66B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.22
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-0.38%
1M Performance:
-9.29%
6M Performance:
-23.97%
1Y Performance:
-37.94%
1-Day Range:
$75.59
$77.56
1-Week Range:
$75.59
$78.20
52-Week Range:
$73.31
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
77.12 | 195.46B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
740.36 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.04 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.80 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.66 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.40 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers - Benzinga
Merck (MRK) Sees Promising Results in Cancer Drug Trial - GuruFocus
Merck releases positive early-stage data on colorectal cancer and NSCLC asset - Seeking Alpha
Merck (MRK) Antibody Drug Shows Promise in Lymphoma Trial - GuruFocus
Merck antibody drug conjugate asset shows antitumor activity in phase 2 - Seeking Alpha
Merck Says Potential Lymphoma Therapy Achieves 56.3% Response Rate in Phase 2 Study - marketscreener.com
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor - marketscreener.com
Merck (MRK) Reports Promising Phase 2/3 Trial Results for Cancer Therapy | MRK Stock News - GuruFocus
Merck reports promising results for cancer drug MK-1084 By Investing.com - Investing.com India
Merck reports promising DLBCL treatment results By Investing.com - Investing.com India
Here’s Why Merck & Co. (MRK) Traded Lower in Q1 - Insider Monkey
Merck reports promising DLBCL treatment results - Investing.com
Merck'S Investigational Zilovertamab Vedotin At 1.75 mg/kg Dose Plus Standard Of Care Showed Promising Antitumor Activity - marketscreener.com
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial - Business Wire
Merck’s West Point Presence Remains Strong Amid Riverside Closure - BUCKSCO.Today
Transcript : Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03 - marketscreener.com
Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS - insights.citeline.com
Merck & Co To Present At Bernstein Strategic Decisions Conference; Webcast At 3:30 PM ET - Nasdaq
Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer - Reuters
Merck & Co. Concludes Annual Shareholders Meeting - TipRanks
Merck shareholders approve board, executive pay at annual meeting By Investing.com - Investing.com India
Merck shareholders approve board, executive pay at annual meeting - Investing.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Merck, Daiichi pull approval application for ADC in lung cancer - BioPharma Dive
Merck: voluntary withdrawal of a BLA in lung cancer - marketscreener.com
Is Merck Stock Underperforming the Nasdaq? - MSN
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Merck (MRK) and Daiichi Sankyo Withdraw U.S. Application for Lung Cancer Therapy - GuruFocus
Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw - marketscreener.com
Is Merck Stock Underperforming The Nasdaq? - Barchart.com
Merck (MRK) Withdraws Biologics License Application for Patritum - GuruFocus
Merck stock drops as BLA for lung cancer drug is pulled (MRK) - Seeking Alpha
Merck Withdraws Biologics License Application for Patritumab Deruxtecan - marketscreener.com
Major Setback: Merck's Advanced Lung Cancer Drug Falls Short in Crucial Survival Trial - Stock Titan
Merck & Co., Inc. (MRK) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Insider Monkey
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results - Yahoo Finance
Abbisko Secures $85 Million from Merck for Pimicotinib Global Rights - TipRanks
Dow falls nearly 250 points on losses in Merck, Nike shares - MSN
Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and Paragangliomas Therapeutics Market | DelveInsight - PR Newswire UK
Merck Votes Overwhelmingly in Support of DEI Amid Backlash - Sustainability Magazine
Merck Proves Why It’s Still A Top Pharma Pick (NYSE:MRK) - Seeking Alpha
Merck (MRK) Options Activity Highlights Bullish Sentiment | MRK Stock News - GuruFocus
Merck & Co., Inc. Declares Quarterly Dividend for the Third Quarter of 2025, Payable on July 8, 2025 - marketscreener.com
Merck sets $0.81 quarterly dividend for Q3 2025 By Investing.com - Investing.com India
Merck Announces Third-Quarter 2025 Dividend - BioSpace
Merck Announces Third-Quarter 2025 Dividend Of $0.81 Per Share - marketscreener.com
NLPC Warns Merck About ‘Materially Misleading’ Shareholders on DEI - National Legal And Policy Center
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors - GlobeNewswire Inc.
Merck & Co.’s SWOT analysis: stock faces keytruda LOE, china challenges - Investing.com
Merck Issues Statement On Potential Reduced Dosing Recommendation For Gardasil 9 - marketscreener.com
Merck: Dividend Near A 12-Year High, But I Won't BuyHere's Why (NYSE:MRK) - Seeking Alpha
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):